Final hours! Save up to 50% OFF InvestingProCLAIM SALE

United to give travelers free COVID-19 tests on select Newark-London flights

Published 2020-10-29, 07:00 a/m
ABT
-
UAL
-

Oct 29 (Reuters) - United Airlines UAL.O said on Thursday it will offer free rapid COVID-19 tests to customers on select transatlantic flights, as part of a four-week pilot program aimed at eventually relaxing quarantines that have crippled air travel.

Chicago-based United said the program would give Abbott Laboratories (NYSE:ABT)' rapid molecular ID Now tests, which take about 15 to 20 minutes, to all passengers above age 2.

The program will run from Nov. 16 through Dec. 11 on three evening flights a week from Newark Liberty International Airport to London's Heathrow Airport.

Global airlines are backing COVID-19 testing to replace or reduce 14-day quarantines and other restrictions that have battered demand. Airline trade group International Air Transport Association (IATA) in September forecasted a 66% decline in overall 2020 air traffic because of the pandemic. passengers from Newark, New Jersey, with a negative test would still be subject to U.K. quarantine requirements, the carrier said.

But customers would have the assurance of flying on a plane where all travelers have tested negative and the program would strengthen the carrier's case to relax quarantines with passenger testing, a company spokesman said

"They (governments) have to make a decision that is rooted in safety and so what we are trying to do is to demonstrate that it is, in fact, safe," Josh Earnest, United's chief communication officer, told reporters.

Since United introduced testing on its San Francisco to Hawaii flights around two weeks ago, the number of people traveling has nearly doubled compared with the two-week period before the test was available, he said. test would be provided by appointment at an on-site testing facility at Newark airport.

Abbott Laboratories said this month its ID NOW COVID-19 rapid test showed 96.2% sensitivity and 99.5% specificity compared to lab-based molecular PCR tests, according to interim data from a study.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.